WO2006016828A8 - Use of alpha ketoglutarate for treating alzheimer, parkinson - Google Patents

Use of alpha ketoglutarate for treating alzheimer, parkinson

Info

Publication number
WO2006016828A8
WO2006016828A8 PCT/PL2005/000051 PL2005000051W WO2006016828A8 WO 2006016828 A8 WO2006016828 A8 WO 2006016828A8 PL 2005000051 W PL2005000051 W PL 2005000051W WO 2006016828 A8 WO2006016828 A8 WO 2006016828A8
Authority
WO
WIPO (PCT)
Prior art keywords
alpha
parkinson
glutarate
keto
apoptosis
Prior art date
Application number
PCT/PL2005/000051
Other languages
French (fr)
Other versions
WO2006016828A2 (en
WO2006016828A3 (en
Inventor
Martyna Kandefer-Szerszen
Wojciech Rezeski
Barbara Zdzisinska
Stefan Pierzynowski
Original Assignee
Sgp & Sons Ab
Martyna Kandefer-Szerszen
Wojciech Rezeski
Barbara Zdzisinska
Stefan Pierzynowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab, Martyna Kandefer-Szerszen, Wojciech Rezeski, Barbara Zdzisinska, Stefan Pierzynowski filed Critical Sgp & Sons Ab
Publication of WO2006016828A2 publication Critical patent/WO2006016828A2/en
Publication of WO2006016828A3 publication Critical patent/WO2006016828A3/en
Publication of WO2006016828A8 publication Critical patent/WO2006016828A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to the use of at least one member selected from the group consisting of alpha-ketoglutarate and its salts: ornithyno-alpha-keto-glutarate, asparagine-alpha-keto-glutarate and other salts with amino acids and salts of alpha-keto-glutarate with metal ions such Na, Ca, Mg, Cu, Sr, Zn, K and others in doses 0.001-1 g/kg/day or in concentration 0.001 mM-100mM for the manufacture of a pharmaceutical preparation and/or food/ feed additive augmenting, supporting the function of the nerve cells and nervous system and simultaneously minimizing, preventing the apoptosis of nerve cells and preventing the development of diseases of nervous system in adolescent, adult and fetuses in mammals, including people, such as Alzheimer, Parkinson, Huntington, Creutzweld-Jakob, BSE and other diseases and protecting the nervous system function against its degeneration due to apoptosis of nerve cells in Alzheimer, Parkinson, Huntington, Creutzweld-Jakob, BSE and other diseases and protecting the growth and stimulating the reproduction and preventing the apoptosis of nerve and other cells in vitro and in biotechnological processes with the use of somatic and bacterial cells .
PCT/PL2005/000051 2004-08-12 2005-08-11 Use of alpha ketoglutarate for treating alzheimer, parkinson WO2006016828A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.369552 2004-08-12
PL369552A PL369552A1 (en) 2004-08-12 2004-08-12 Pharmaceutical or/and nutrient or/and laboratory preparation for increasing, supporting the functioning of nerve cells and nervous system as well as application of pharmaceutical or/and nutrient or/and laboratory preparation in protection of the functions

Publications (3)

Publication Number Publication Date
WO2006016828A2 WO2006016828A2 (en) 2006-02-16
WO2006016828A3 WO2006016828A3 (en) 2006-06-08
WO2006016828A8 true WO2006016828A8 (en) 2007-07-19

Family

ID=35462217

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2005/000051 WO2006016828A2 (en) 2004-08-12 2005-08-11 Use of alpha ketoglutarate for treating alzheimer, parkinson

Country Status (2)

Country Link
PL (1) PL369552A1 (en)
WO (1) WO2006016828A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590173B2 (en) 2010-02-18 2023-02-28 Osiris Therapeutics, Inc. Methods of manufacture of therapeutic products comprising vitalized placental dispersions

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6263540B2 (en) * 2012-09-19 2018-01-17 グレスポ・アクチボラゲットＧｒｅｓｐｏ ＡＢ Composition for improving brain function
US20150328176A1 (en) * 2013-01-25 2015-11-19 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US20200253907A1 (en) * 2017-08-21 2020-08-13 The Regents Of The University Of California Compositions and Methods for Treating Neurodegenerative Diseases
CN117530940A (en) * 2023-10-11 2024-02-09 四川大学华西第二医院 Application of alpha-ketoglutarate in preparation of medicines for promoting myelin repair and improving neuroinflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9402027D0 (en) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
EP1032403B1 (en) * 1997-10-24 2012-05-02 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
DE19755367C2 (en) * 1997-12-12 2001-03-22 Afting Ernst Guenter Pharmaceutical composition containing D-galactose and its use
US20050085498A1 (en) * 1998-05-28 2005-04-21 Byrd Edward A. Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate
US6093743A (en) * 1998-06-23 2000-07-25 Medinox Inc. Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
US20020193335A1 (en) * 2001-03-02 2002-12-19 Hesson David P. Gene therapy for neurological tissues
FR2822704B1 (en) * 2001-03-29 2005-02-18 Chiesi Sa SALTS OF KETOACIDES AND GASTRORESISTANT AMINO ACIDS AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS
NZ530554A (en) * 2004-01-13 2004-04-30 A Neuronutrients

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590173B2 (en) 2010-02-18 2023-02-28 Osiris Therapeutics, Inc. Methods of manufacture of therapeutic products comprising vitalized placental dispersions

Also Published As

Publication number Publication date
PL369552A1 (en) 2006-02-20
WO2006016828A2 (en) 2006-02-16
WO2006016828A3 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2006016828A8 (en) Use of alpha ketoglutarate for treating alzheimer, parkinson
WO2009000552A3 (en) Compositions for the treatment of hyperphenylalaninemia
SG179120A1 (en) Novel compounds
MX2009000333A (en) Pyrrolopyrimidines for pharmaceutical compositions.
MY147488A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
TW200745003A (en) Novel compounds
IN2006KO01346A (en)
EP1032403A4 (en) Nutritional supplement for cerebral metabolic insufficiencies
MX2008012479A (en) Treatment of neurodegenerative diseases.
WO2008046810A3 (en) Alleles of the rel gene of coryneform bacteria
MY146238A (en) Prodrugs of excitatory amino acids
MY142029A (en) Phenoxyacetic acid derivatives
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
PL1951729T3 (en) Oxygen linked pyrimidine derivatives
MX2021009868A (en) Novel pyrido[3,4-d]pyrimidin-8-one derivative having protein kinase inhibitory activity, and pharmaceutical composition for preventing, alleviating, or treating cancer, comprising same.
MX2008012422A (en) Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors.
MY138708A (en) Biaryloxymethylarenecarboxylic acids
AU2018381574A1 (en) Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor
WO2022031847A3 (en) Compositions and methods for inhibiting plp1 expression
MX2008002487A (en) Use of dextrin in animal feeds.
MX2009003406A (en) Use of particular antibacterial compounds, which are derived from alliaceae, as natural additives in animal feed.
Yamamoto et al. Desensitization by different strategies of epidermal growth factor receptor and ErbB4
WO2005077332A3 (en) Stable sustained-release oral dosage forms of gabapentin and process for preparation thereof
WO2020197059A3 (en) Method for inducing differentiation of stem cells into cartilage cells, using folic acid, folic acid derivative, or folic acid inhibitor
WO2004100885A3 (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase